Trial Court Dismissal of Zofran Birth Defect Lawsuits Upheld on Appeal Before First Circuit
The dismissal of hundreds of Zofran birth defect lawsuits was upheld by a federal appeals court which determined GlaxoSmithKline did not have the authority to change the drug's label warnings.